Navigation Links
Cepheid Reports 2012 First Quarter Results
Date:4/19/2012

 Three Months Ended March 31,20122011ChangeClinical Systems

$
2.5$
.68%Clinical Reagents

54.438.641%Total Clinical 66.950.233%Non-Clinical

8.47.413%Total Product Sales$
75.3$
57.631%--

By geography, product sales were, in millions: Three Months Ended March 31,20122011ChangeNorth AmericaClinical

$
45.5$
36.325%Non-Clinical

6.95.916%Total North America52.442.224%InternationalClinical

21.413.954%Non-Clinical

1.51.52%Total International22.915.449%Total Product Sales$
75.3$
57.631% 

--

During the quarter, Cepheid installed a total of 122 GeneXpert systems in its commercial Clinical business.  Additionally,
the Company placed a total of 151 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.
Including the HBDC systems, a cumulative total of 3,079 GeneXpert systems have been placed worldwide as of March 31, 2012.

 --

GAAP gross margin on product sales was 53% and non-GAAP gross margin on product sales was 54%, which compares to
56% and 58%, respectively, in the first quarter of 2011.  Gross margin was impacted by higher than expected costs associated
with freight and with the scale-up of our manufacturing operations, in addition to higher Group Purchasing Organization (GPO)
fees recorded as contra revenue. 

 --

GAAP research and development (R&D) expense was 29% of total revenue and non-GAAP research and development expense
was 26% of total revenue, which compares to 23% and 20%, respectively, in the first quarter of 2011.  R&D expense included
higher than expected costs associated with the early completion of our CT/NG trial, including an increase in patient enrollment.

 --

Cash and cash equivalents were $104.0 million as of March 31, 2012.

 --

DSO was 42 days.Busine
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cepheid Schedules 2011 Third Quarter Financial Results Announcement and Webcast
2. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast
5. Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner
6. Cepheid Appoints Vice President of Infectious Disease Research & Development
7. LABSCO to Distribute Cepheid GeneXpert® Systems and Tests
8. Cepheid Appoints LABSCO as US Small Hospital Distributor
9. Cepheid Reports 2011 First Quarter Results
10. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
11. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... upcoming prestigious Minimally Invasive Surgery Symposium (MISS) will include ... to colon surgery, single-port bariatric surgery, transoral gastroplasty, and ... made today by MISS Executive Director Philip R Schauer, ... faculty. , The five-day CME conference, which will ...
... Calif., Oct. 27 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... teleconference with management to provide a general business overview, as ... Tuesday, November 3, 2009, at 5:00 p.m. Eastern Time (2:00 ... ended September 30, 2009 will be released earlier that day. ...
Cached Medicine Technology:Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego 2
(Date:4/18/2014)... a brain-related discovery that could revolutionize doctors, perception ... opens up the possibility that environmental and/or genetic ... activity that the researchers have identified as helping ... Neuroscience has just published a paper about ... of psychology and his doctoral student John Gaspar, ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... together nine research groups from seven countries, including teams ... and Israel, has recently been set up with the ... active sensing adopted widely in the animal kingdom, the ... ,whiskered, robotic rat. The whiskered robot will be able ...
... Medical Directions, Inc. (MDI),an independent digital medical education ... education program dealing with the,management of chronic pain ... live lectures by national experts., The study, ... Neurological,Disorders and Stroke (NINDS), was reported February 5, ...
... as better informed patients make ever-increasing demands and expect ... decisions that directly affect their care. In a ... Dr. J. Bohannon Mason of the Orthocarolina Hip and ... changes in society, the population and technology that are ...
... for Second Consecutive Year, STAMFORD, Conn., Feb. ... packaging and marketing process management,service, today announced it ... a,row by the readers of Consumer Goods Technology ... year, Paxonix was recognized with a,Best in Class ...
... Lumenis(R) Ltd. announced,today that it has scheduled a special ... accordance with the Israeli Companies,Law, of a proposed settlement ... against the Company in the federal court in New ... which has been,agreed to in principle by Lumenis and ...
... Financial Team, METAIRIE, La., Feb. 11 ... and dental practices,worldwide, has named Michael P. Beland ... responsible for all aspects of the Company,s,accounting, tax, ... am pleased that we have been able to ...
Cached Medicine News:Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 2Health News:Scientists from Europe, Israel and the US develop robotic rats to aid in rescue missions 3Health News:Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts 2Health News:Doctor who? Are patients making clinical decisions? 2Health News:Paxonix Recognized for Exemplary Support in New Product Development and Implementation 2Health News:Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement 2Health News:Michael Beland Named as OrthoSynetics(TM) Corporate Controller 2
Use to prevent arm or leg drops during surgical procedures. The dimensions are 10"W x 6"H. These come in pairs. Optional Gel pad available (BD2245)...
... Precision Dynamics Corporation offers a ... serving infants to adults. Armboard ... non-woven material assuring easy cleaning ... cross contamination. Choose from three ...
... to fit almost every operating table. 3/D ... the sit of fixation to the operating ... be titled to any position the surgeon ... adjustment of the 3/D Swinger permits rotation ...
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Medicine Products: